Patents Represented by Attorney Bonnie L. Deppenbrock
  • Patent number: 7732622
    Abstract: A compound of formula (I) wherein R1 and R3 are the same or different and represent ?O, hydrogen, C1-6alkyl, C1-6dialkyl, ?CHC1-C5alkyl, ?S, or a 5- or 6-membered aryl; R4 to R9 are the same or different and represent hydrogen, C1-6alkoxy, OCF3, OCH2CF3, O-cyclopropyl, OCH2-cyclopropyl, C1-C6alkyl, S-alkyl, NR210 where R10 is hydrogen or C1-6alkyl, halogen, NO2, OH, CH2OC1-C6alkyl, CH2OH, or CF3; Q1 is hydrogen, C1-6alkyl, C1-6dialkyl, C1-6alkoxy, NHAc, NR210 where R10 is hydrogen or C1-6alkyl, difluoro, fluoro, ?O, or OH; Q2, Q3, Q4 and Q5 are the same or different and represent hydrogen, C1-6alkoxy, OCF3, OCH2CF3, O-cyclopropyl, OCH2-cyclopropyl, C1-C6alkyl, S-alkyl, NR210 where R10 is hydrogen or C1-6alkyl, halogen, NO2, OH, CH2OC1-C6alkyl, CH2OH, or a 5- or 6-membered aryl; with the proviso that the compounds [4-(1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl)phenyl]-2-propionic acid, sodium salt and [4-(4,9-diethoxy-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl)phenyl]acetic acid are excluded; and pharmac
    Type: Grant
    Filed: April 30, 2008
    Date of Patent: June 8, 2010
    Assignee: Glaxo Group Limited
    Inventors: Miles Stuart Congreve, Gerard Martin Paul Giblin, Andrew McMurtrie Mason, Neil Derek Miller, Susan Roomans, Ann Louise Walker
  • Patent number: 7718689
    Abstract: A compound of formula (I) or a pharmaceutically acceptable derivative thereof, wherein R1 to R8, X, and Y are as defined in the specification; a process for preparing such compounds; a pharmaceutical composition comprising such compounds; and the use of such compounds in medicine.
    Type: Grant
    Filed: February 12, 2007
    Date of Patent: May 18, 2010
    Assignee: Glaxo Group Limited
    Inventors: Mark Patrick Healy, Gerard Martin Paul Giblin, Neil Derek Miller
  • Patent number: 7713978
    Abstract: The present invention relates to compounds of formula (I) processes for their preparation, pharmaceutical compositions containing the same and to their use in the treatment of gastrointestinal and other disorders.
    Type: Grant
    Filed: March 29, 2007
    Date of Patent: May 11, 2010
    Inventors: Nigel Paul King, Jason Witherington
  • Patent number: 7645338
    Abstract: The present invention includes (E)-2-(5-Chlorothien-2-yl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}ethenesulfonamide in substantially crystalline form, pharmaceutical formulations thereof, processes for preparing it, and its use in medicine, particularly use in the amelioration of a clinical condition for which a Factor Xa inhibitor is indicated.
    Type: Grant
    Filed: December 4, 2003
    Date of Patent: January 12, 2010
    Assignee: Glaxo Group Limited
    Inventors: Philip C. Dell 'Orco, Henry Anderson Kelly, Gita Punjabhai Shah, Nigel Stephen Watson, Robert John Young
  • Patent number: 7645771
    Abstract: The present invention relates to compounds of formula (I) or a pharmaceutically acceptable derivatives thereof, useful in the treatment of prophylazis of CCR5-related diseases and disorders, for example, in the inhibition of HIV replication, the prevention or treatment of HIV infection, and in the treatment of the resulting acquired immune deficiency syndrome (AIDS).
    Type: Grant
    Filed: December 12, 2003
    Date of Patent: January 12, 2010
    Assignee: SmithKline Beecham Corp.
    Inventors: Wieslaw Mieczyslaw Kazmierski, Chrisopher Joseph Aquino, Neil Bifulco, Eric Eugene Boros, Brian Andrew Chauder, Pek Yoke Chong, Maosheng Duan, Felix Deanda, Jr., Cecilia Suarez Koble, Ed Williams McLean, Jennifer Poole Peckham, Angilique C Perkins, James Benjamin Thompson, Dana Vanderwall
  • Patent number: 7638631
    Abstract: The present invention relates to novel methylene dipiperidine derivatives having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurological and psychiatric disorders.
    Type: Grant
    Filed: September 16, 2005
    Date of Patent: December 29, 2009
    Assignee: Glaxo Group Limited
    Inventors: Gordon Bruton, Vicky Johnstone, Barry Sidney Orlek
  • Patent number: 7592347
    Abstract: The present invention relates to novel piperidine carbonyl piperazine derivatives having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurological and psychiatric disorders.
    Type: Grant
    Filed: April 21, 2004
    Date of Patent: September 22, 2009
    Assignee: Glaxo Group Limited
    Inventors: Gordon Bruton, Barry Sidney Orlek, Kishore Kalidas Rana
  • Patent number: 7589204
    Abstract: The present invention relates to compounds of formula (I), or pharmaceutically acceptable derivatives thereof, useful in the treatment of CCR5-related diseases and disorders, for example, useful in the inhibition of HIV replication, the prevention or treatment of an HIV infection, and in the treatment of the resulting acquired immune deficiency syndrome (AIDS).
    Type: Grant
    Filed: April 1, 2009
    Date of Patent: September 15, 2009
    Assignee: SmithKline Beecham Corporation
    Inventors: Michael Youngman, Wieslaw Mieczyslaw Kazmierski, Hanbiao Yang, Christopher Joseph Aquino
  • Patent number: 7589207
    Abstract: The present invention relates to compounds of formula (I), or pharmaceutically acceptable derivatives thereof, useful in the treatment of CCR5-related diseases and disorders, for example, useful in the inhibition of HIV replication, the prevention or treatment of an HIV infection, and in the treatment of the resulting acquired immune deficiency syndrome (AIDS).
    Type: Grant
    Filed: December 12, 2003
    Date of Patent: September 15, 2009
    Assignee: SmithKline Beecham Corporation
    Inventors: Maosheng Duan, Wieslaw Mieczyslaw Kazmierski, Christopher Joseph Aquino
  • Patent number: 7569579
    Abstract: The present invention relates to compounds of formula (I), or pharmaceutically acceptable derivatives thereof, useful in the treatment of CCR5-related diseases and disorders, for example, useful in the inhibition of HIV replication, the prevention or treatment of an HIV infection, and in the treatment of the resulting acquired immune deficiency syndrome (AIDS).
    Type: Grant
    Filed: December 12, 2003
    Date of Patent: August 4, 2009
    Assignee: SmithKline Beecham Corporation
    Inventors: Jennifer Poole Peckham, Christopher Joseph Aquino, Wieslaw Mieczyslaw Kazmierski
  • Patent number: 7560453
    Abstract: The present invention relates to radiolabelled compounds of formula (I), which are useful for the labelling and diagnostic imaging of histamine H3 receptor functionality.
    Type: Grant
    Filed: January 5, 2006
    Date of Patent: July 14, 2009
    Assignee: Glaxo Group Limited
    Inventor: Christophe Plisson
  • Patent number: 7560568
    Abstract: The present invention provides compounds of formula (I): wherein all variables are as defined herein, pharmaceutical compositions containing the same, processes for preparing the same and their use as pharmaceutical agents.
    Type: Grant
    Filed: December 2, 2004
    Date of Patent: July 14, 2009
    Assignee: SmithKline Beecham Corporation
    Inventor: Kyle Allen Emmitte
  • Patent number: 7531661
    Abstract: The present invention relates to compounds of formula (I), or pharmaceutically acceptable derivatives thereof, useful in the treatment of CCR5-related diseases and disorders, for example, useful in the inhibition of HIV replication, the prevention or treatment of an HIV infection, and in the treatment of the resulting acquired immune deficiency syndrome (AIDS).
    Type: Grant
    Filed: December 12, 2003
    Date of Patent: May 12, 2009
    Assignee: SmithKline Beecham Corporation
    Inventors: Michael Youngman, Wieslaw Mieczyslaw Kazmierski, Hanbiao Yang, Christopher Joseph Aquino
  • Patent number: 7514446
    Abstract: The present invention provides compounds of formula (I): wherein all variables are as defined herein, pharmaceutical compositions containing the same, processes for preparing the same and their use as pharmaceutical agents.
    Type: Grant
    Filed: February 11, 2004
    Date of Patent: April 7, 2009
    Assignee: SmithKline Beecham Corporation
    Inventors: Ronda Davis-Ward, Robert Anthony Mook, Jr., Michael J Neeb, James M Salovich
  • Patent number: 7465807
    Abstract: The present invention provides a process for preparing benzimidazole thiophene compounds.
    Type: Grant
    Filed: October 12, 2004
    Date of Patent: December 16, 2008
    Assignee: SmithKline Beecham Corporation
    Inventors: Mui Cheung, Kyle Allen Emmitte
  • Patent number: 7452992
    Abstract: The present invention relates to compounds of formula (I), or pharmaceutically acceptable derivatives thereof, useful in the treatment of CCR5-related diseases and disorders, for example, useful in the inhibition of HIV replication, the prevention or treatment of an HIV infection, and in the treatment of the resulting acquired immune deficiency syndrome (AIDS).
    Type: Grant
    Filed: December 12, 2003
    Date of Patent: November 18, 2008
    Assignee: SmithKline Beecham Corporation
    Inventors: Christopher Joseph Aquino, Pek Yeng Chong, Maosheng Duan, Wieslaw Mieczyslaw Kazmierski
  • Patent number: 7446103
    Abstract: The present invention relates to novel bicyclic benzamide derivatives having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurological and psychiatric disorders.
    Type: Grant
    Filed: October 20, 2003
    Date of Patent: November 4, 2008
    Assignee: Glaxo Group Limited
    Inventors: Desmond John Best, Barry Sidney Orlek
  • Patent number: 7442693
    Abstract: There is provided novel diazepines that function as agonists at the melanocortin 4 receptor and as agonists at the melanocortin 1 receptor, pharmaceutical compositions containing them, methods for their use in treatment, and processes for their preparation.
    Type: Grant
    Filed: May 27, 2005
    Date of Patent: October 28, 2008
    Assignee: SmithKline Beecham Corporation
    Inventors: Jerzy Ryszard Szewczyk, Jason Daniel Speake, Douglas McCord Sammond, Ronald George Sherrill
  • Patent number: 7381728
    Abstract: The invention provides compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein Ra, Rb, Rc, Rd, Re, Rf and Y are as defined in the specification. The compounds are partial or full agonists at the growth hormone secretagogue (GHS) receptors. Pharmaceutical compositions comprising the compounds methods of preparing the compounds, uses of the compounds and methods involving the compounds are also provided.
    Type: Grant
    Filed: July 26, 2005
    Date of Patent: June 3, 2008
    Assignee: Glaxo Group Limited
    Inventors: David Kenneth Dean, Alessandra Gaiba, Nigel Paul King, Andrew Kenneth Takle, Jason Witherington
  • Patent number: 7354966
    Abstract: Compounds of formula (I): and uses of such compounds are described.
    Type: Grant
    Filed: March 4, 2003
    Date of Patent: April 8, 2008
    Assignee: Glaxo Group Limited
    Inventors: Brian Edgar Looker, Christopher James Lunniss, Alison Judith Redgrave